Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

What Will Happen When Rebates Go Away? Look At Authorized Generics

Recent launches by Lilly, Amgen and Gilead suggest list prices may decrease with the HHS proposal to disrupt the rebate system, but not as low as current net prices after rebates, according to pharmacy benefit experts.

Pricing Strategies Regulation

The PBM Business Model, As Told To Sen. Cornyn

Execs offer (mostly) consistent responses as congressmen come out of the woodwork to grill the PBMs on their business practices.
Pharmacy Benefit Management Legislation

Insulin Prices: House Hearing Displays Bipartisan Commitment To Rapid Reform

Reform "is going to happen,” promised Energy & Commerce Oversight Subcommittee Chair Diana DeGette, suggesting the panel’s next hearing on insulin price reform may be held in July.

Pricing Debate Legislation

Senate Panel Questions Early PBM Response To Repatha Price Cut

Rebate expectations appear to have got in the way of fast uptake for some of the leading pharmacy benefit managers, according to comments by executives at the Senate Finance Committee hearing April 9.

Reimbursement Pricing Debate

CMS Offers Part D Plans Financial Backstop If Rebates Eliminated In 2020

But CMS also advises Medicare Part D plans to develop bids for the 2020 plan year that include rebates, since the final version of the HHS rule eliminating the anti-kickback safe harbor for rebates may not be released in time for the June 3 bid submission deadline. 

Regulation Reimbursement

Express Scripts Insulin Program Lowers Cost Sharing With Supplemental Manufacturer Discounts

New wrinkle on lowering out-of-pocket spending differs from point-of-sale rebates and manufacturer copay assistance cards, the PBM says, and is not expected to increase plan costs.

Reimbursement Pharmacy Benefit Management
See All
Advertisement
UsernamePublicRestriction

Register